We leveraged the number and molecular diversity of the cell lines to investigate synergy rate, biomarkers and clinical trials for combinations screened in three populations with unmet clinical need: patients with basal-like breast cancer (n = 22), MSS colon cancer (n = 31) or KRAS-mutant colon cancer (n = 25). The gene discussed is KRAS; the disease is malignant colon neoplasm.